StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the medical equipment provider’s stock. Other equities ...

Shares of Nevro Corp. (NYSE:NVRO – Get Free Report) have earned a consensus rating of “Reduce” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. Two investment ...

Spinal cord stimulators have grown in popularity over the past several years as patients see benefits in the less-invasive ...

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A 24-month study compared CMM alone versus Nevro’s high-frequency (10 kHz) spinal cord stimulation (SCS) system for treating NSRBP. In April 2024, Medtronic plc, a world leader in medical technology, ...

a responsive and personalized pain management platform that powers the HFX iQ spinal cord stimulation (SCS) system. In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system ...